Skip to contentL
Ligand Pharmaceuticals Inc
L
LGNDLigand Pharmaceuticals Inc Q1 2017 · 10-Q
Revenue$56.16M$56.16M+89.4% vs Q1 2016 Net Income$45.28M$45.28M+585.2% vs Q1 2016 EPS Diluted$1.83$1.83+510.0% vs Q1 2016 Operating Income$10,216,000−32.3% Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Ligand Pharmaceuticals Inc · CIK 886163 · Engraved from SEC EDGAR
Free Cash Flowderived$19,137,000+48.6% Margins · derivedOperating margin18.2%−32.7 pt vs Q1 2016
Net margin80.6%+58.3 pt vs Q1 2016
ended Mar 31, 2017 · filed May 9, 2017 · 39 d after period end